Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease

Lancet Neurol. 2010 Dec;9(12):1200-1213. doi: 10.1016/S1474-4422(10)70212-X. Epub 2010 Sep 27.

Abstract

Cognitive impairment in patients with Parkinson's disease is gaining increased clinical significance owing to the relative success of therapeutic approaches to the motor symptoms of this disorder. Early investigations contributed to the concept of subcortical dementia associated with bradyphrenia and cognitive rigidity. For cognition in parkinsonian disorders, this notion developed into the concept of mild cognitive impairment and fronto-executive dysfunction in particular, driven mainly by dopaminergic dysmodulation and manifesting as deficits in flexibility, planning, working memory, and reinforcement learning. However, patients with Parkinson's disease could also develop a syndrome of dementia that might depend on non-dopaminergic, cholinergic cortical dysfunction. Recent findings, supplemented by advances in neuroimaging and genetic research, reveal substantial heterogeneity in the range of cognitive deficits in patients with Parkinson's disease. Remediation and management prospects for these cognitive deficits are based on neuropharmacological and cognitive rehabilitation approaches.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cholinergic Agents / therapeutic use
  • Cognition Disorders* / etiology
  • Cognition Disorders* / genetics
  • Cognition Disorders* / therapy
  • Cognitive Behavioral Therapy / methods
  • Dementia / etiology*
  • Dementia / genetics
  • Dopamine Agents / therapeutic use
  • Genetic Predisposition to Disease*
  • Genetic Testing / methods
  • Humans
  • Neuropsychological Tests
  • Parkinson Disease* / complications
  • Parkinson Disease* / genetics
  • Parkinson Disease* / psychology

Substances

  • Cholinergic Agents
  • Dopamine Agents